Abstract

Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables high evolvability but their evolution has not been investigated. Here we apply multi-region exome sequencing (MSeq) to four treatment-naive dMMR GOAs. This reveals extreme intratumour heterogeneity (ITH), exceeding ITH in other cancer types >20-fold, but also long phylogenetic trunks which may explain the exquisite immunotherapy sensitivity of dMMR tumours. Subclonal driver mutations are common and parallel evolution occurs in RAS, PIK3CA, SWI/SNF-complex genes and in immune evasion regulators. MSeq data and evolution analysis of single region-data from 64 MSI GOAs show that chromosome 8 gains are early genetic events and that the hypermutator-phenotype remains active during progression. MSeq may be necessary for biomarker development in these heterogeneous cancers. Comparison with other MSeq-analysed tumour types reveals mutation rates and their timing to determine phylogenetic tree morphologies.

Tumours that are deficient in mismatch-repair genes should, in theory, have higher evolvability. Here, the authors explore this theory in gastro-oesophageal tumours.

Details

Title
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
Author
von Loga Katharina 1   VIAFID ORCID Logo  ; Woolston, Andrew 2   VIAFID ORCID Logo  ; Punta, Marco 3 ; Barber, Louise J 2 ; Griffiths, Beatrice 2 ; Semiannikova, Maria 2 ; Spain, Georgia 2 ; Challoner, Benjamin 2   VIAFID ORCID Logo  ; Fenwick, Kerry 4 ; Simon, Ronald 5 ; Marx, Andreas 6 ; Sauter Guido 5 ; Stefano, Lise 3   VIAFID ORCID Logo  ; Matthews, Nik 4 ; Gerlinger Marco 7   VIAFID ORCID Logo 

 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); The Royal Marsden Hospital, Biomedical Research Centre, London, United Kingdom (GRID:grid.424926.f) (ISNI:0000 0004 0417 0461) 
 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623) 
 The Institute of Cancer Research, Bioinformatics Core, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623) 
 The Institute of Cancer Research, Tumour Profiling Unit, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623) 
 University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484) 
 University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484); University Hospital Fuerth, Institute of Pathology, Fuerth, Germany (GRID:grid.411668.c) (ISNI:0000 0000 9935 6525) 
 The Institute of Cancer Research, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, London, United Kingdom (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); The Royal Marsden Hospital, Gastrointestinal Cancer Unit, London, United Kingdom (GRID:grid.424926.f) (ISNI:0000 0004 0417 0461) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2342490374
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.